Trial | NCT00534183  Report issue

Official Title

Metabolic Profile and Anthropometric Changes in Schizophrenia

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    2006
"No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "
we aimed to study the effects of antipsychotics, olanzapine, risperidone and haloperidol on development of metabolic syndrome in a drug naïve population suffering from first episode schizophrenia and compared it with a matched healthy control group. We also aimed to examine the prevalence of metabolic syndrome as defined by the two most widely accepted definitions, the ATP IIIA and the IDF.
Study Started
Jun 30
2006
Study Completion
Dec 31
2006
Last Update
Sep 24
2007
Estimate

Drug Olanzapine

Olanzapine in dose range of 10-20mg

Drug Risperidone

Risperidone 1-6mg

Drug Haloperidol

Haloperidol 10-20mg

1 Experimental

Olanzapine

2 Active Comparator

Risperidone

3 Active Comparator

haloperidol

Criteria 

Inclusion Criteria:

Age between 18-40 years
Diagnosis of schizophrenia
Drug naive on admission

Exclusion Criteria:

Other psychiatric co-morbidity
History of severe physical illness
Alcohol and substance abuse or dependence
History of pre-existing diabetes or hypertension
Family history of hypertension or diabetes
No Results Posted